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ABSTRACT
We have previously shown that melatonin exerts tumor suppressor activities 
by inducing the p38-p53 axis. This occurred within a few hours while no data are 
available on how melatonin pathway can be sustained on the long term. Here we show 
that miR-24, which has been demonstrated to target genes involved in the DNA repair 
process, targets p38, p53, PML and H2AX simultaneously. We show that long-term 
treatment with melatonin can decrease miR-24 levels post-transcriptionally, which 
pairs with a long-wave regulation of genes involved in cell proliferation, DNA damage, 
RNA metabolism and cell shape and transformation. Moreover, we show that melatonin 
can inhibit cell proliferation and migration, at least in part, by downregulating miR-24.  
Furthermore, we propose the involvement of hnRNP A1, which is downregulated by 
melatonin and involved in miRNA processing, in the regulation of miR-24 levels by 
melatonin. We conclude showing that miR-24 is upregulated in colon, breast and head 
and neck datasets and its levels negatively correlate with overall survival.
INTRODUCTION
Melatonin exerts a plethora of activities, among 
which radical scavenging and activation of tumor suppressor 
pathways [1–12]. These activities explain in part the negative 
correlation observed between melatonin levels and the risk 
of developing cancer. In particular, it is worth to mention 
three epidemiological prospective studies conducted 
on healthy subjects, two of them on the ORDET cohort 
[13, 14] and the third one on the Nurses’ Health cohort [15], 
which showed a negative correlation between the urinary 
6-sulphatoxymelatonin (aMT6s) levels and breast cancer risk.
A few studies have shown that melatonin can 
activate phosphorylation cascades, mediated by MEK1/2, 
ERK1/2, JNK and p38 MAPK [10, 11, 16, 17], through 
binding to its G protein-coupled membrane receptors 
MT1 and MT2. This leads to the activation of tumor 
suppressor pathways, such as p53. In particular, melatonin 
treatment induces a p38-mediated phosphorylation of p53 
in Ser15, which caused a transient cell cycle arrest and 
the accumulation of DNA repair proteins (e.g. H2AX 
and PML) and the induction of DNA repair mechanisms 
themselves [6, 10]. These phenomena occur only in the 
presence of intact MT1 and MT2 signalling [11]. 
These studies have been conducted on short 
intervals and showed fast phosphorylation kinetics, at 
least concerning p53. Although it is evident that melatonin 
activities are sustained over long periods of time (e.g. 
increase in p53 levels following 72 hours treatment 
with melatonin), no data are available on their long-
term regulation. Being deregulated in many cancers and 
involved in the carcinogenic process [18–21], micro-RNAs 
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(also known as miRNAs and miRs) are good candidates 
for long-term regulation of tumor suppressive pathways, 
such as p53. They are small non-coding RNAs [22], which 
regulate gene expression by inducing degradation or 
inhibiting translation of their numerous target genes [23]. 
They are transcribed as a long primary RNA (pri-miRNA or 
pri-miR), which usually contains multiple miRNAs. Before 
leaving the nucleus, pri-miRs are cleaved by Drosha and 
DGCR8 [24–27] into a smaller precursor RNA (pre-miRNA 
or pre-miR). pre-miR is then exported into the cytoplasm 
[28–30], where Dicer cleaves it into 22 nucleotides long 
double-stranded miRNAs [31, 32]. These are bound by 
the RNA-induced Silencing Complex (RISC), which 
catalyzes the separation of the two complementary strands, 
indicated as mature miR-5p and miR-3p (reviewed in 
[33]). Both strands are able to regulate gene expression 
and show different target genes [34]. They can also elicit 
sometimes completely different outcomes, as in the case of 
miR-10b and miR-10b*. Indeed, overexpression of miR-
10b positively regulates cell migration and invasion in 
metastatic- and its overexpression initiates robust invasion 
and metastasis in non-metastatic breast tumors [35], while 
overexpression of miR-10b* associates with longer relapse- 
and metastasis-free survival [18, 36].
Being such an important process, miRNA 
processing is tightly regulated by several proteins. Apart 
from Dicer-binding proteins [25, 37–41], RNA-binding 
proteins concur to miRNA maturation. Heterogeneous 
Nuclear Ribo-Nucleo-Proteins (hnRNPs) have recently 
been shown to be involved in miRNA processing, the 
most known examples being probably the involvement of 
hnRNP A1 in the maturation of miR-18a [42, 43].
A variety of miRNAs regulate the DNA repair 
process by targeting DNA repair proteins [44], among 
which miR-24, which regulates histone H2AX expression, 
thereby causing genomic instability and reducing DNA 
repair [45]. miR-24 has been found in both pleural 
effusions and sera from patients with lung cancer, 
therefore it is now regarded to as a potential diagnostic 
tumor marker [46, 47]. In addition, miR-24 is upregulated 
in highly differentiated CD8+ T cells upon etoposide 
treatment and associated with a decreased DNA damage 
response [48] and in oral squamous cell carcinomas 
(OSCC) as compared to their matched controls [49], as 
well as in hepatocellular carcinomas (HCC), its expression 
being higher in higher grade HCC [50]. Moreover, miR-24 
is overexpressed in glioblastomas and promotes cell 
growth and migration in glioma cells both in vitro and 
in vivo [51]. 
In the present manuscript, we show that melatonin 
downregulated miR-24, which targets four components 
of the melatonin activated pathway: p38, p53, PML and 
H2AX. By targeting these genes, miR-24 enhance cell 
proliferation and induce migration of cancer cells, while 
melatonin can revert these phenotypes in the presence of 
physiological levels of miR-24 but not when miR-24 is 
overexpressed by mimic transfection. We also show that 
miR-24 downregulation occur through intact MT1/MT2 
receptor signalling, as it is abolished in the presence of the 
melatonin antagonist Luzindole. In addition, we propose 
the involvement of hnRNP A1 in the processing of miR-
24, since miR-24 downregulation by melatonin seems 
to occur at the post-transcriptional level and melatonin 
downregulates hnRNP A1 expression through receptor 
signalling.
RESULTS 
Melatonin downregulates miR-24 leading to 
upregulated expression of its targets
We have previously shown that melatonin 
activates the p53 pathway with a fast kinetics through 
stimulation of its membrane receptors, MT1 and MT2 
[10, 11]. However, it remained unclear how melatonin 
could sustain the p53 pathway activation on the long 
term, which would eventually lead to inhibition of 
cell proliferation and protection from DNA damage 
accumulation. To clarify this, we performed a search 
in silico to identify miRNAs predicted to regulate the four 
components of the melatonin pathway: p53, p38, PML 
and H2AX. We used the microRNA.org database and 
identified 60 miRNAs putatively targeting all four genes 
simultaneously. Among those, only five had validated 
targets in Tarbase: miR-24, miR-217, miR-296–5p, 
miR-324–3p and miR-876–3p (Table 1). miR-24 (alias 
miR-24–3p) raised our interest as it showed the highest 
number of validated targets, it had been previously 
reported to target H2AX and inhibit DNA repair [45]. It 
is also upregulated in a variety of cancers as compared to 
non-tumoral tissues (Supplementary Figure S1). We also 
interrogated the expression of predicted miR-24 putative 
target genes in a RNA-Seq experiment previously 
performed in our laboratory in vehicle and melatonin 
treated cells for 48 hours, to look at global changes in 
mRNA expression following melatonin treatment. We 
identified 14 upregulated genes following melatonin 
treatment which were also miR-24–3p putative targets 
(Table 2). Among the 14 genes we identified H2AX and 
p38-γ (Figure 1A). To assess whether miR-24 could be 
regulated by melatonin, we measured its expression levels 
after treatment with melatonin of both HCT 116 and 
MCF-7 cells. We found that miR-24 levels were strongly 
reduced following 72 hours of melatonin treatment in 
both cell lines and this appear already evident at 48 hours 
in MCF-7 cells (Figure 1B). This prompted us to validate 
our four genes of interest as targets of miR-24. We 
analyzed their expression upon miR-24 transfection by 
Dual Luciferase assays, Real-Time qPCR and Western 
Blot. Dual Luciferase assays confirmed that all four 
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genes were direct targets of miR-24 (Figure 1C) and 
deletion of the seed sequence of miR-24 abolished their 
regulation by miR-24 (Figure 1C). Both Real-Time 
qPCR and Western Blot analyses showed that p53, p38 
and PML expression was decreased upon transfection 
of miR-24 (Figure 1D, 1F). H2AX was downregulated 
by miR-24 at the mRNA but not protein level, probably 
due to the targeting of a specific 3ʹUTR variant of H2AX 
by miR-24. Conversely, inhibition of miR-24 expression 
by LNA transfection induced the expression of p38, p53, 
PML and H2AX both at the mRNA (Figure 1E) and 
the protein (Figure 1G) levels. miR-24 overexpressed 
and downregulated levels are monitored by qPCR 
(Supplementary Figure S2A–S2B). Strikingly, p38, p53, 
PML and H2AX transcripts are up-regulated in response 
to melatonin thus it is opposite to that of miR-24 upon the 
identical experimental conditions in both HCT 116 and 
MCF-7 cell lines (Figure 2A).
miR-24 causes genomic instability
We have previously reported that melatonin can 
reduce DNA fragmentation caused by chemotherapeutic 
administration through activation of the p38-p53 axis 
[10, 11]. Lal et al., have shown that miR-24 causes DNA 
damage through downregulation of histone H2AX [45]. 
We reasoned that, p53- and p38-dependent DNA repair 
induced by melatonin could be mediated by its ability 
to reduce miR-24 expression levels. To this purpose, we 
assessed DNA damage accumulation in HCT 116 cell lines 
stably overexpressing miR-24 (miR-Vec-24) or its negative 
control (miR-Vec). Our results confirmed that miR-24 
could increase DNA damage induced by chemotherapy as 
assessed by comet assays (Figure 2B–2C). Interestingly, 
melatonin was able to reduce DNA fragmentation only 
when miR-24 was expressed at physiological levels 
(Figure 2B–2C). This suggests that melatonin’s ability 
to protect cells from DNA damage is exerted, at least in 
part, through downregulation of miR-24 levels. miR-24 
stably overexpressed levels are verified in qPCR analysis 
(Supplementary Figure S2C). 
Melatonin inhibits miR-24-mediated 
proliferation and migration
Melatonin has been shown to inhibit cell 
proliferation through activation of p53 [6, 8, 10, 11]. 
We found that inhibition of miR-24 expression by 
LNA transfection reduced HCT 116 cells proliferation 
(Figure 3A). As miR-24 has been shown to regulate 
migration and invasion [52], we performed transwell 
migration assays in the presence or in the absence of 
melatonin in HCT 116 and HCC1143 cells transfected 
with either control or mimic-24. Melatonin inhibited 
cell migration at physiological levels of miR-24, which 
per se enhanced the percentage of migrating cells, while 
this ability was lost when miR-24 was overexpressed 
(Figure 3B–3C). Similar findings were found by LNA-
mediated inhibition of miR-24 expression (Figure 3D–3E). 
miR-24 downregulated levels are verified in qPCR analysis 
(Supplementary Figure S2D). To understand whether 
melatonin and miR-24 regulated the invasive processes 
through the p38-p53 axis, we performed transwell 
migration assays in the presence and in the absence of the 
p38 inhibitor SB202190, which we previously showed to 
impair melatonin-induced p38-mediated phosphorylation 
of p53 [10]. Melatonin reduced partially the migration of 
HCT 116 cells in the presence of SB202190, but the extent 
of reduction was far lower (Figure 3F).
These results were corroborated by wound healing 
assays in HCC1143 cells: melatonin inhibited the 
wound healing process, while blockage of p38 impaired 
melatonin’s ability to reduce wound closure (Figure 3G). 
Both sets of data suggest that, at least, part of melatonin 
inhibitory activity towards migration is exerted through 
the p38 signalling.
Melatonin downregulates miR-24 through 
inhibition of hnRNP A1
We reported that melatonin anticancer activities 
are exerted mainly through activation of MT1 and 
MT2 receptors [11]. To ascertain whether downregulation 
Table 1: miRNAs targeting the melatonin-p53 pathway
Micro-RNA Validated targets
hsa-miR-24 217
hsa-miR-217 10
hsa-miR-296–5p 8
hsa-miR-324–3p 3
hsa-miR-876–3p 1
miRNAs targeting p38, p53, PML and H2AX have been predicted by microRNA.org. Only 5 out of 60 miRNAs targeting 
simultaneously the four genes had validated targets in Tarbase and have been listed in the Table according to the number of 
validated targets.
Oncotarget20535www.impactjournals.com/oncotarget
Figure 1: miR-24 targets the melatonin-p53 pathway. (A) Graphs show the sequence coverage, as well as the signal intensity, of 
H2AFX (H2AX) and MAPK12 (p38-γ) in both vehicle and melatonin treated HCT 116 cell line. (B) HCT 116 and MCF-7 cells have been 
treated with melatonin for 24, 48 and 72 hours. The ratio between miR-24 and RNU49 levels, normalized to their respective untreated 
controls, are indicated in the graphs. (C) HCT 116 cells have been transfected with either negative control (NC) or miR-24 mimic and the 
indicated Dual Luciferase reporters. Values for NC are set to 1. *p < 0,01. (D, E) HCT 116 and MCF7 cells have been transfected with the 
indicated mimic (D) or LNA (E) and subjected to quantitative Real-Time PCR. Values have been normalized to NC or LNA. (F, G) Cells 
have been transfected with the indicated mimic (F) or LNA (G) and cell extracts have been subjected to immunoblot with the indicated 
antibodies. Numbers indicate signal quantification normalized to NC or LNA-NC.
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of miR-24 by melatonin could be exerted through MT1 
and MT2, we investigated miR-24 expression levels 
following melatonin treatment in the absence and in the 
presence of the melatonin receptors inhibitor Luzindole. 
Quantitative Real-Time PCR revealed that blockage 
of melatonin receptors impaired melatonin’s ability to 
reduce miR-24 levels (Figure 4A). Likewise, inhibition 
of p38 activity by treatment with SB202190 impaired 
miR-24 downregulation by melatonin (Figure 4B), 
suggesting that miR-24 expression was regulated through 
the p38-mediated melatonin receptor signalling. 
miR-24 is transcribed from two different clusters: 
miR-23b~27b~24–1 and miR-23a~27a~24–2 [53]. To 
understand whether miR-24 was regulated at either 
the transcriptional or the post-transcriptional level 
by melatonin, we examined the expression levels of 
miR-23a, miR-23b, miR-27a and miR-27b. Interestingly 
their expression did not seem to vary upon melatonin 
treatment (Figure 4C), suggesting that the two clusters 
were not regulated transcriptionally. To corroborate these 
results, we amplified both pri-miR-24 and pre-miR-24 
by Real-Time qPCR, both in the absence and in the 
presence of melatonin. Interestingly, while we could not 
appreciate a variation in the ratio between pre-miR-24–1 
and pri-miR-24–1, the ratio between pre-miR-24–2 
and pri-miR-24–2 increased upon melatonin treatment 
(Figure 4D), this may suggest that in the presence of 
melatonin pre-miR-24–2 would not be converted to 
mature miR-24. 
Given that melatonin treatment induced the 
expression of miR-24 target genes (Table 2), which 
are involved in cell proliferation (WDR18, PRELID1, 
CRLF1, TMEM115), cell shape and transformation 
(TAGLN, REEP6), RNA metabolism (RPS23, RPL10) 
and DNA damage response (RFC2, MAPK12, H2AFX), 
we reasoned that miR-24 downregulation could be a major 
event in melatonin anticancer activities. Therefore, we 
searched for a possible regulator of miR-24 maturation 
in a proteomic screening previously performed in our 
laboratory, to look at global changes in protein expression 
following melatonin treatment (data not shown). We 
found that hnRNP A1, a protein involved in both mRNA 
splicing and miRNA maturation [42, 43, 54–56], was 
downregulated upon melatonin treatment (data not 
shown). We confirmed this finding by Western Blot 
(Figure 5A). Of notice, hnRNP A1 mRNA levels were 
not affected by melatonin treatment (Supplementary 
Figure S3), suggesting a post-transcriptional regulation 
by melatonin.
To confirm hnRNP A1 involvement in miR-24 
maturation, we overexpressed hnRNP A1 and treated the 
cells with melatonin. While melatonin led to a decrease 
in miR-24 at physiological levels of hnRNP A1, we could 
not observe a decrease in miR-24 when hnRNP A1 was 
overexpressed (Figure 5B), suggesting that melatonin-
induced miR-24 downregulation was exerted through 
inhibition of hnRNP A1 expression. We then sought to 
analyze whether the decrease in hnRNP A1 levels occurred 
Table 2: miR-24–3p putative target genes regulated by melatonin
Gene Transcript FPKM_ctrl FPKM_mel log2 p-value q-value
ATAD3B NM_031921 2.47 3.62 0.55 0.0005 0.0371
CRLF1 NM_004750 1.95 3.16 0.69 0.0005 0.0371
H2AFX NM_002105 23.57 33.43 0.50 0.0001 0.0077
MAPK12 NM_002969 12.98 17.16 0.40 0.0005 0.0392
MRPL27 NM_016504 56.10 72.29 0.37 0.0006 0.0449
NCLN NM_020170 3.24 4.40 0.44 0.0006 0.0449
PRELID1 NM_013237 22.11 35.90 0.70 0.0001 0.0130
REEP6 NM_138393 5.00 7.21 0.53 0.0004 0.0312
RFC2 NM_181471 19.74 27.92 0.50 0.0004 0.0312
RPL10 NM_006013 56.79 76.97 0.44 0.0001 0.0077
RPS23 NM_001025 168.56 213.37 0.34 0.0002 0.0205
TAGLN NM_003186 2.30 4.49 0.97 0.0001 0.0130
TMEM115 NM_007024 2.32 3.67 0.66 0.0001 0.0130
WDR18 NM_024100 6.60 9.63 0.55 0.0001 0.0077
miR-24 putative target genes upregulated following melatonin treatment in HCT 116 cells. FPKM, p- and q-values, as well 
as the log2 value, are shown. 
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through activation of melatonin membrane receptors. To 
this purpose, we knocked down the expression of MT1 
and MT2 by siRNA and investigated hnRNP A1 protein 
levels. Results showed that removal of either receptors led 
to an increase of hnRNP A1 protein levels (Figure 5C). 
miR-24 and hnRNP A1 are deregulated in 
human cancers
We investigated miR-24 expression levels in both 
colon and breast cancer datasets. For colon cancer we 
used the Pan-Cancer colorectal adenocarcinoma dataset 
[57, 58], comprising 314 cases and 11 controls, while 
for breast cancer we interrogated both the METABRIC 
[59] and the TCGA [60] databases, comprising 1284 
cases (208 basal-like) and 116 controls, and 694 cases 
(90 basal-like) and 83 controls, respectively. We found that 
miR-24 levels were far higher in tumor vs normal samples 
in both datasets for colorectal carcinoma (Figure 6A). We 
observed a statistically significant upregulation of miR-24 
in the basal-like breast cancer subtype as compared to 
normal samples (Figure 6B) for breast cancer. Kaplan-
Meier analyses in the METABRIC dataset showed 
that high miR-24 levels correlated with a lower disease 
specific survival rate (Figure 6C). To verify that miR-24 
acted as an oncogene in diverse cancer types, we analyzed 
its expression from our head and neck squamous cell 
carcinomas dataset [61]. We found that, also in this dataset, 
Figure 2: Melatonin induces the expression of the p53-pathway and alleviates genomic instability caused by miR-24. 
(A) HCT 116 and MCF-7 cell lines have been treated or not with melatonin for 72 hours and the expression levels of the indicated mRNAs 
were assessed by quantitative Real-Time PCR. Values have been normalized to untreated control. *p < 0,01. (B) HCT 116 cell lines stably 
expressing miR-Vec or (C) miR-Vec-24 have been pre-treated with either vehicle or melatonin, then DNA damage has been induced as 
indicated (CDDP: Cisplatin, Doxo: Doxorubicin, UVB: Ultra Violet B rays). Cells have been subjected to comet assay. Histograms show 
the percentage of comets.
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Figure 3: Melatonin impairs the capability of miR-24 to induce cell proliferation and migration. (A) Cells were transfected 
with the indicated LNA and allowed to proliferate. Percentage of cells relative to control is indicated in the graph. *p < 0,05. (B) HCT 116 
and (C) HCC1143 cells were transiently transfected with either NC or mimic-24 and subjected to transwell migration assays in the absence 
and in the presence of melatonin. Histograms show the percentage of invading cells. *p < 0,001. (D) HCT 116 cells were transfected 
with the indicated LNA and subjected to wound healing assay. Histograms show the percentage of wound opening. *p < 0,05. (E) HCT 
116 were transfected with the indicated LNA and subjected to transwell migration assay. Histograms show the percentage of invading cells. 
*p < 0,01. (F) HCT 116 cells have been treated with 5 µM SB202190 for 2 hours and then subjected to transwell migration assay. *p < 0,05. 
(G) HCC1143 cells have been subjected to wound healing assay in the absence and in the presence of SB202190 and melatonin. Histograms 
show the percentage of wound opening. *p < 0,05.
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Figure 4: Regulation of miR-24 levels by melatonin. (A) HCT 116 and MCF-7 cells have been either pretreated or not with 
Luzindole 15 minutes before melatonin treatment and miR-24 levels have been quantified 72 h later by quantitative Real-Time PCR. 
Histograms show miR-24/RNU49 levels relative to untreated control. *p < 0,01. (B) HCT 116 cells have been treated with melatonin for 
72 hours in the absence and in the presence of 5 µM SB202190. Histograms show miR-24/RNU49 levels relative to untreated control. 
*p < 0,01. (C) HCT 116 and MCF-7 cells were treated with melatonin for 72 h. Levels of expression of the indicated miRNAs were 
assessed by quantitative Real-Time PCR. (D) HCT 116 and MCF-7 cells were treated with melatonin for 72 h. Histograms show the ratio 
between pre-miR-24–1 and pri-miR-24–1 and the ratio between pre-miR-24–2 and pri-miR-24–2 levels. *p < 0,01. 
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miR-24 was upregulated in tumors as compared to non-
tumoral matched samples (Figure 6D) and that high levels 
of miR-24 correlated with a lower survival (Figure 6E). 
These data, together with the proliferation and migration 
data shown in Figure 3, corroborate our and others finding 
that miR-24 acts as an oncogenic microRNA [52, 62]. 
A few reports have shown that hnRNP A1 is 
deregulated in human cancers [63, 64]. We verified the 
upregulation of hnRNP A1 in both colon and breast cancer, 
by analyzing its expression in four colon (Supplementary 
Figure S4A) and four breast (Supplementary Figure S4B) 
cancer datasets in Oncomine (www.oncomine.org) 
[59, 63–69]. We found it overexpressed in tumor vs 
normal samples. These data might suggest hnRNP A1 
involvement in both colon and breast cancer.
DISCUSSION
Epidemiological studies have shown that melatonin 
levels negatively correlate with the risk of developing 
various kinds of cancers [13–15]. We have previously 
shown that melatonin can induce the p38-p53 axis 
through membrane receptor activation [10, 11]. However, 
while our previous data focused on a fast kinetics of 
induction of the p38-p53 axis occurring within 3 hours of 
treatment (Figure 7, green arrows), others have observed 
an upregulation of p53 at later time points [3, 6, 8] but 
there is no evidence of how melatonin can exert its long-
term oncostatic effects. A possible mechanism could be 
miRNA regulation. However, at present there is only one 
report about miRNAs regulation by melatonin, in which 
the authors identified a set of miRNAs differentially 
modulated in untreated and treated MCF-7 cells [70] but 
neither the mechanisms by which melatonin can influence 
miRNA expression nor the mechanisms by which 
miRNAs can regulate melatonin’s anticancer activities 
are known. Our work identifies the oncogenic miR-24 
as a miRNA strongly repressed by melatonin 72 hours 
post treatment (Figure 7, red arrow), which has p38, 
p53, PML and H2AX among its target genes (Figure 1). 
In addition, we identified 14 putative targets of miR-24 
after melatonin treatment (Table 2), among which H2AX 
and p38-γ. Of notice, H2AX had the highest mirSVR 
score (Supplementary Table S1), which could account 
Figure 5: hnRNP A1 is involved in the regulation of miR-24 levels. (A) HCT 116 and MCF-7 cells were treated with melatonin 
for 72 h and protein extracts were subjected to immunoblot with the indicated antibodies. Numbers indicate the densitometry ratio between 
hnRNP A1 and 20Sα5 signals. (B) HCT 116 cells were transfected with the indicated plasmids and treated with melatonin for 72 h, miR-24 
levels were assessed by quantitative Real-Time PCR. *p < 0,01. (C) HCT 116 and MCF-7 were transfected with the indicated siRNAs. 72 h 
post transfection, cell lysates were subjected to immunoblot with the indicated antibodies. Numbers indicate the densitometry ratio between 
hnRNP A1 and tubulin or nucleolin signals, normalized to siGFP. 
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Figure 6: Clinical association of miR-24 with survival and recurrence in cancer patients. (A) Box plot showing miR-24 
median value in 314 cancer cases and 11 controls belonging to the Pan-Cancer Colon and rectal adenocarcinoma datasets. (B-C) Box plot 
showing miR-24 median value in 208 basal-like cancers and 116 controls (METABRIC) and 90 basal-like cancers and 83 controls (TCGA) 
(B) and association between expression levels of miR-24 and disease-free survival evaluated by Kaplan-Meier analysis in the METABRIC 
dataset, comprising 1284 cases and 116 controls (C). (D–E) Box plot showing miR-24 median value in 121 cancer cases and 66 controls (D) 
and association between expression levels of miR-24 and recurrence-free survival evaluated by Kaplan-Meier analysis (E) in our HNSCC 
casuistry [61].
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for the fact that it was upregulated already 48 hours post 
treatment, when we observed a mild downregulation of 
miR-24 (Figure 1B). The decrease in miR-24 expression 
following melatonin treatment translated into activation 
of DNA repair and inhibition of cell proliferation and 
migration, due in part to the upregulation of the four key 
components of the melatonin receptor activated pathway 
(Figures 2 and 3). Thus, upon melatonin treatment, 
p38 induced a mechanism of self-sustainment through 
downregulation of miR-24 (Figure 4B). Our data on the 
melatonin-induced p38-dependent reduction of hnRNP 
A1 protein are supported by previous observations 
reporting that p38 can phosphorylate hnRNP A1 [71, 72], 
thereby changing its localization from the nucleus to 
stress granules in the cytoplasm, as well as reducing its 
protein levels [73]. Previous reports have also shown 
that hnRNP A1 can bind to miRNA precursors and 
regulate their cleavage acting as a miRNA chaperone 
[42, 43]. We suggest that hnRNP A1 mediates miR-24 
processing in the absence of melatonin, as its ectopic 
expression abrogates miR-24 downregulation. We reported 
previously that melatonin membrane receptors MT1 and 
MT2 could be involved in the carcinogenic process, 
since their expression is lower in tumors as compared 
to normal samples [11]. Conversely, here we show that 
hnRNP A1 is upregulated in tumor vs normal samples 
in the same colon cancer casuistries where we observed 
repression of MT1 and MT2 and in an additional casuistry 
as well (Supplementary Figure S4A). This occurs also 
in four breast cancer casuistries deposited in Oncomine 
(Supplementary Figure S4B). Despite we show that 
miR-24 targets four crucial proteins involved in melatonin 
anticancer effects, this does not rule out the possibility 
that other target proteins as well as other miRs will play a 
major role in such activities. 
miR-24 is regarded to as an oncogenic miRNA 
in various types of cancer because not only it targets 
DNA repair genes, such as H2AX [44, 45] but it has 
also been found upregulated in OSCC [49] (Figure 6D), 
hepatocellular carcinoma [50], glioblastoma [51] and 
breast cancer [74]. In addition, it is involved in the 
carcinogenic process by inducing transformation and 
migration [50, 51]. Our data provide evidence for 
both miR-24 oncogenic role in breast and colon cancer 
and melatonin inhibition of an oncogenic pathway. 
First, we provide evidence that miR-24 contributes to 
transformation of breast and colon cancer cell lines, as it 
conferred a higher proliferative and migratory potential 
to HCT 116 and HCC1143 cells and that its ectopic 
expression could overcome melatonin repression of these 
oncogenic features (Figure 3). Then, we show that miR-24 
is upregulated in colon cancer, as well as in breast cancer. 
Figure 7: Model of melatonin activities. By binding to its receptors (MT1/MT2), Melatonin induces p38 expression. With a fast 
kinetics (green arrow), Melatonin induces phosphorylation of p53 and H2AX thereby promoting DNA repair and inhibiting cell proliferation. 
Long-term activation of Melatonin receptors sustains p38 activation and leads to inhibition of hnRNP A1 (red arrow) thereby causing a 
decrease in miR-24, which results in p53, PML, H2AX and p38 activity reduction. Through downregulation of hnRNP A1 and miR-24, 
melatonin impairs the migrating capability of cancer cells.
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In particular, its expression levels are higher in colorectal 
adenocarcinoma as compared to normal samples in the 
Pan-Cancer casuistry, and in the basal-like subtype of 
breast cancer in the METABRIC and TCGA datasets 
(Figure 6A–6B). Moreover, we evaluated the association 
between expression levels of miR-24 and recurrence-free 
survival by Kaplan-Meier analysis and found a strong 
negative correlation for breast cancer (Figure 6C). As for 
breast cancer, we found that miR-24 was overexpressed 
in head and neck tumors and higher levels correlated 
with a worse prognosis (e.g. worse disease-free survival) 
(Figure 6D–6E). This suggests that miR-24 deregulation 
could be a carcinogenic event common to various types 
of cancer. Recently, miR-24 has been identified as a 
circulating miRNA in lung cancer patients. It has been 
found, together with miR-30d, as a cell-free miRNA in 
both malignant and benign pleural effusions, with higher 
levels in the malignant ones [47], as well as in pre-
operation sera from lung cancer patients [46]. In the light 
of these observations, miR-24 could be used as a potential 
cancer biomarker. 
These data strengthen the role of melatonin as a 
chemopreventive agent. In fact, we can speculate that not 
only melatonin could induce DNA repair (Figure 2B–2C) 
[75], thereby restraining the side effects of radio- and 
chemo-therapy on normal cells, but it could per se 
reduce migration and invasion, through downregulation 
of miR-24, thus ameliorating the prognosis of invasive 
cancers. Obviously, this speculation needs to be validated 
by assessing the impact of melatonin treatment on the 
DNA repair of untransformed cells. The use of melatonin 
as an adjuvant for both chemo- and radio-therapy could 
therefore be envisioned in patients with metastatic cancers 
and could be used as a therapeutic approach in tumors 
harboring p53 wild-type. In aggregate, it emerges that 
melatonin treatment instigates the activation of a tumor 
suppressor network, which finely tunes transcriptional 
events and non-coding mRNAs activity. The outputs of 
such network might depend from both the type and the 
stage of a given tumor. 
MATERIALS AND METHODS
Cell culture and transfection
HCT 116 and MCF-7 cells (ATCC, Manassas, 
US) were cultured in DMEM supplemented with 10% 
FCS, 2 mM L-Glutamine, 100 Units/ml Penicillin and 
100 µg/ml Streptomycin (Gibco, Life Technologies, 
Carlsbad, CA, US). HCC1143 cells were cultured in 
DMEM-F12 supplemented with 10% FCS, 100 Units/ml 
Penicillin and 100 µg/ml Streptomycin. Cell lines were 
grown at 37°C, 5% CO2. Transfections were performed 
with Lipofectamine 2000 and Lipofectamine RNAiMax 
(Life Technologies, Carlsbad, CA, US) according to the 
manufacturer’s recommendations, using either negative 
control (NC) (cat. 4464061, Life Technologies, Carlsbad, 
CA, US) or mimic-24 (MC10737, Life Technologies, 
Carlsbad, CA, US) or LNA-control (LNA) or 
LNA-miR-24–3p (LNA miR-24) (Exiqon A/S, Vedbaek, 
Denmark). MT1 and MT2 receptors were silenced in 
HCT 116 cell line using siRNAs: siGFP 5′-AAGUUCA
GCGUGUCCGGGGAG(dTdT)-3′; siMTNR1A 5′-GG
AAUACAGGAGAAUUAUA(dTdT)-3′; siMTNR1B 
5′-CUAGCUACUUACUGGCUUA(dTdT)-3′ (Eurofins 
MWG, Ebersberg, Germany). HCT 116 stable cell lines 
were generated by stable transfection of HCT 116 cells 
with either miR-Vec or miR-Vec-24 and selected for 
2 weeks with 2 μg/ml Blasticidin (15205 Sigma-Aldrich, 
Saint Louis, Missouri, US).
Reagents
Melatonin (1 μM, M5250), Luzindole (1 nM, 
L2407) and SB 202190 (5 μM, S7067) were purchased 
from Sigma-Aldrich (Saint Louis, Missouri, US).
Mutant constructs
Plasmid mutant constructs have been generated 
by deleting miR-24 seed sequences in the parental 
Dual Luciferase Reporter constructs by Quick Change 
mutagenesis (Agilent Technologies, California, US) 
following manufacturer’s instructions. The following 
primers have been used:
p38 del 645–666 FW: 5ʹ-GTTAAAAGACTGCAGC
GGGCAAGTCGAGAGGG-3ʹ; p38 del 645–666 Rev: 5ʹ-
CCCTCTCGACTTGCCCGCTGCAGTCTTTTAAC-3ʹ;  
H2AX del 74–95 FW 5ʹ-ACCACCGCCCTCATGGAAA
GCTTCAGACTGC-3ʹ; H2AX del 74–95 Rev 5ʹ-GCAG
TCTGAAGCTTTCCATGAGGGCGGTGGT-3ʹ; H2AX 
del 956–977 FW 5ʹ-GATACCAGCAGAAGTCGGTTAA 
TCCGTTGGCTTCT-3ʹ; H2AX del 956–977 Rev 5ʹ-AG 
AAGCCAACGGATTAACCGACTTGTGCTGGTATC-3ʹ; 
PML del 40–61 FW 5ʹ-GGGATGGGGTCCAGGCCCCA 
CCCA-3ʹ; PML del 40–61 Rev 5ʹ-TGGGTGGGGCCT 
GGACCCCATCCC-3ʹ; PML del 1928–1958 FW 5ʹ-GCA 
GTCTGAAGCTTTCCATGAGGGCGGTGGT-3ʹ; PML 
del 1928–1958 Rev 5ʹ-GGATTCACATGCTTAAGA
GGGCTCTCAGCTCTGC-3ʹ; p53 del 827–845 FW 
5ʹ-GAGTGGAGTGGCGTTTTGCCTCCCCGGC-3ʹ; p53 
del 827–845 Rev 5ʹ-GCCGGGGAGGCAAAACGCCA 
CTCCACTC-3ʹ.
Growth curves
HCT 116 cell line, transfected with either 
LNAcontrol (LNA) or LNA-miR-24–3p (LNA miR-24) 
(Exiqon A/S, Vedbaek, Denmark) were allowed to 
proliferate and viability was measured at 24 h, 48 h and 
72 h by ATPlite assay (Perkin Elmer, Whaltman, MA, 
US), according to manufacturer’s instructions.
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Dual luciferase assays
5 × 103 cells were reverse transfected with either 
negative control or miR-24 mimic into 12-well dishes; 
48 hours later, they were transfected with the indicated 
reporter constructs. After additional 24 hours, cells 
were lysed and subjected to Dual Luciferase assays on a 
GloMax 96 Microplate Luminometer (Promega, Madison, 
WI 53711 US), using the Dual Luciferase Reporter assay 
system (E1910, Promega, Madison, WI 53711 US). For the 
psiCheck2-based H2AX (kind gift of Dr. Ashish Lal) and 
p53 (kind gift of Prof. Moshe Oren) reporter constructs 
(Promega, Madison, WI 53711 US), having the 3ʹUTR of 
interest downstream the Renilla Luciferase, experiments 
have been conducted in triplicate and graphs show the 
ratio between Renilla and Firefly luciferase. As for the 
pEZX-MT01-based p38 and PML reporter constructs 
(Genecopoeia, Rockville, US), having the 3ʹUTR of 
interest downstream the Firefly Luciferase, experiments 
have been conducted in six replicate and values for Firefly 
Luciferase have been reported in the graphs. Student t-test 
has been used to calculate p-values.
Western blots
Protein extracts were prepared as previously 
described [11]. All protein extracts were quantified by 
Bradford assay and equal amounts were loaded onto 
SDS–PAGE, transferred to polyvinylidene fluoride 
membranes (PVDF, Immobilon-P, Merck-Millipore, 
Life Science, Darmstadt, Germany) and subjected to 
immunoblot with the indicated antibodies. Antibodies 
to β-actin (A2288, AC-74, Sigma-Aldrich, Saint Louis, 
Missouri, US), 20Sα5 (ab11437 AbCam, Cambridge, UK), 
Tubulin (Ab18251 AbCam, Cambridge, UK), Nucleolin 
(ab13541, 4E2, Abcam, Cambridge, UK), MTNR1A 
(MT1) (ab87639, AbCam, Cambridge, UK), MTNR1B 
(MT2) (ab128469, AbCam, Cambridge, UK) p38 (9212, 
Cell Signaling, Danvers, MA, US), PML (sc5621, H-238, 
Santa Cruz Biotechnology, CA, US), p53 (sc126, DO1, 
Santa Cruz Biotechnology, CA, US), hnRNP A1 (8443, 
D21H11, Cell Signaling, Danvers, MA, US), H1 (sc34464, 
Santa Cruz Biotechnology, CA, US), H2AX (#2595 Cell 
Signaling, Danvers, MA, US) were diluted in 5% bovine 
serum albumin in Tris-buffered-saline/0.1% Tween-20. 
Secondary anti-mouse, anti-goat and anti-rabbit antibodies 
were purchased from Bio-Rad (Bio-Rad, Hercules, 
CA, US). Images were acquired using a VersaDoc MP 
instrument (Bio-Rad, Hercules, CA, US). 
Comet assays
Following transfection with the indicated constructs, 
cells were treated with melatonin for 2 hours and then 
subjected to DNA damaging treatments with CDDP 
(850 nM, TEVA, Italia, Italy), Doxorubicin (10 nM, 
Ebewe, Pharma, Austria) and 5-Fluorouracile (1,5 µM, 
Hospira, Illinois, US), or Ultra Violet B (UVB) irradiated 
at a dose of 0,05 J/cm2 using a Bio-Sun irradiation 
apparatus (Vilbert Lourmat, Marne-la-Vallée, France) and 
allowed to repair DNA for 4 hours. After treatment, cells 
were detached with trypsin and subjected to comet assay 
as described previously [10, 11]. DNA was stained with 
propidium iodide (Sigma-Aldrich, Saint Louis, Missouri, 
US) and pictures were taken using 60x magnification on 
an Axiovert 200 M microscope and Axiovision acquisition 
program (Zeiss, Oberkochen, Germania). At least 300 cells 
were scored for each slide.
Transwell migration assays
Transfected cells were detached and counted. 
5 × 104 cells, in a volume of 100 µl DMEM containing 
0,1% FBS, were seeded in the upper chamber while the 
bottom chamber of the transwell was filled with 600 µl 
of DMEM with 10% FBS. Either melatonin or ethanol 
was added to the upper chamber. Cells were allowed to 
migrate for 20 hours. Then cells remaining in the upper 
chamber were scrubbed away with a cotton pad and cells 
remaining on the bottom layer of the upper chamber were 
subjected to DAPI staining as follows: the upper chamber 
was washed twice with PBS and then cells were fixed 
with 4% formaldehyde for 20 minutes, permeabilized with 
0,2% Triton for 25 minutes and, after being washed with 
PBS, they were stained with 5 µM DAPI for 5 minutes. 
Membranes were cut and mounted on microscopy slides. 
All the cells on each membrane were counted. Each 
sample was assayed in triplicate. Graphs show percentage 
of cells relative to control. Student t-test has been used to 
calculate p-values.
RNA extraction, reverse transcription and 
quantitative real-time PCR
RNA was extracted with Trizol (Life Technologies, 
Carlsbad, California, US) following manufacturer’s 
instruction and quantified using Nanodrop (Thermo 
Scientific, Waltham, Massachusetts, US). For mRNA, 
500 ng RNA were reverse-transcribed with M-MLV 
reverse transcriptase (Life Technologies, Carlsbad, 
California, US) following manufacturer’s instruction 
and 1/10 of the reverse transcription was subjected to 
Real-Time PCR using FAST SYBR Green mastermix 
(4385612, Life Technologies, Carlsbad, California, US). 
The following primers were used: 
p53 FW 5ʹ-GTCTGGGCTTCTTGCATTCT-3ʹ; p53 
Rev 5ʹ-AATCAACCCACAGCTGCAC-3ʹ; p38 alpha FW 
5ʹ-GTGCCCGAGCGTTACCAGAAC-3ʹ; p38 alpha Rev 
5ʹ-CTGTAAGCTTCTGACATTTC-3ʹ; PML FW 5ʹ-CGCC 
CTGGATAACGTCTTT-3ʹ; PML Rev 5ʹ-ACTGTGGCTG 
CTGTCAAGG; H2AX 3ʹUTR FW 5ʹ-AGCAAACTCA 
ACTCGGCAAT-3ʹ; H2AX 3ʹUTR Rev 5ʹ-ACTCCCCA 
ATGCCTAAGGTT-3ʹ; beta actin FW 5ʹ-GGCATGGGTC 
AGAAGGATT-3ʹ; beta actin Rev 5ʹ-CACACGCAGCT 
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CATTGTAGAAG-3ʹ; hnRNP A1 FW 5ʹ-ATACTTTGCA 
AAACCACGAAACC-3ʹ; hnRNP A1 RV 5ʹ-CCTGCTA 
AGCTTTGTTTCCTAATTAAA-3ʹ; pri-miR-24–1 FW 
5ʹ-GCGGTGAACTCTCTCTTGTA-3ʹ; pri-miR-24–1 RV 
5ʹ-TTACAGACACGAAGGCTTTT-3ʹ; pre-miR-24–1 FW 
5ʹ-GGTGCCTACTGAGCTGAT-3ʹ; pre-miR-24–1 RV 
5ʹ-CTGTTCCTGCTGAACTGAG -3ʹ; pri-miR-24–2 FW 
5ʹ-GTTCACAGTGGCTAAGTTCC-3ʹ; pri-miR-24–2 RV 
5ʹ-ATCTCTGCTCCAAGCATCA-3ʹ; pre-miR-24–2 FW 
5ʹ-GTGCCTACTGAGCTGAAA-3ʹ; pre-miR-24–2 RV 
5ʹ-CTGTTCCTGCTGAACTGAG-3ʹ.
miRNA were reverse transcribed from 10 ng RNA 
using the TaqMan® microRNA Reverse transcription 
kit (4366596, Life Technologies, Carlsbad, California, 
US). 1 µl of the reaction was used for Real-Time PCR. 
Amplification was carried out using specific miRNA 
probes and the TaqMan® Universal PCR Master Mix, no 
AMP erase UNG (4364343, Life Technologies, Carlsbad, 
California, US) in a 7500 Fast Real Time instrument (Life 
Technologies, Carlsbad, California, US). Student t-test has 
been used to calculate p-values.
RNA-Seq
Total RNA from melatonin or vehicle treated HCT 
116 cells was isolated using miRNeasy including the 
optional DNase treatment (Qiagen, Valencia, CA, US). 
RNA quality was verified using an Agilent Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, US; RNA 
6000 Nano kit). All RNAs used for subsequent library 
preparation had an RNA integrity number greater than 9.0. 
RNA libraries for sequencing were generated according to 
the Epicenter ScriptSeq v2 RNA-Seq library preparation 
kit with an initial ribosomal depletion step using Ribo-
Zero Magnetic Gold. Starting material was 5 µg of total 
RNA. Based on qPCR quantification, libraries were 
normalized to 1 nM and denatured by using 0.1 N NaOH. 
Cluster amplification of denatured templates was carried 
out according to manufacturer protocol (Illumina, Inc., 
San Diego, CA, US). Sequencing was performed on a 
Genome Analyzer IIx (Illumina, Inc., San Diego, CA, US) 
in paired-end mode, sequencing 2 × 75 bp. For each 
sample generated by the Illumina platform, a pre-process 
step for quality control has been performed to assess 
sequence data quality and to discard low quality reads. 
For the analysis we exploited the RNA-Seq analysis 
workflow RAP [76] , that comprises of read mapping, 
transcript assembly and abundancy estimation followed 
by transcript-based differential expression via the Tuxedo 
suite [77]. Paired-end reads were mapped to the human 
genome assembly hg19 with TopHat and further analyzed 
by the Cufflinks-Cuffdiff pipeline to identify differentially 
expressed transcripts. We run the pipeline without novel 
transcript discovery, correcting for multiply mapping reads 
with the “-u” option of Cuffdiff and a mask file for rRNAs 
and tRNAs. The RNA-Seq was conducted with three 
biological replicates. 
Putative miR-24–3p targets were identified using 
the predictive target search of miRWalk [78] with the 
programs DIANAmT, miRanda, miRDB, miRWalk, 
RNA22 and Targetscan, taking only those genes in 
consideration that were predicted to be miR-24–3p targets 
by at least 3 different programs. Differentially expressed 
genes and transcripts that are putative miR-24–3p targets 
are reported in Table 2, along with p-value and q-value as 
reported by Cuffdiff.
Statistical analyses 
No statistical method was used to predetermine 
sample size. Experiments were not randomized. For 
biochemical experiments we performed the experiments 
at least three independent times. Experiments for which 
we showed representative images were performed 
successfully at least 3 independent times. No samples 
were excluded from the analysis. The investigators were 
not blinded to allocation during experiments and outcome 
assessment. All p-values were determined using two-tailed 
t-tests and statistical significance was set at p = 0.05. The 
variance was similar between groups that we compared. 
For head and neck patients’ samples, the ethical committee 
of the “Regina Elena” National Cancer Institute (protocol 
CE/379/08) approved the study and informed consent was 
obtained. 
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